Psoriatic Arthritis Belgium 2025: NF-kB IL-17A, Enthesis & Ginger

SCIENTIFIC SUMMARY

Psoriatic arthritis (PsA) affects 20-30% of Belgian psoriasis patients, approximately 120,000 individuals. It is a spondyloarthritis at the intersection of cutaneous psoriasis, peripheral arthritis, and enthesopathy. Central mechanism: cutaneous/intestinal dysbiosis -> dendritic cells -> IL-23 -> Th17 expansion -> IL-17A -> entheseal NF-kB and synoviocytes -> entheseal pannus formation + marginal erosions + periostitis. Specificity of PsA vs RA: the enthesis (tendon insertion) is the primary inflammation in PsA, not the synovium as in RA. IL-17A is the dominant cytokine vs TNF-alpha in RA. 6-Gingerol: synoviocytes IL-17A -35%, entheseal NF-kB -40%, IL-23 production by DC -28%, TNF-alpha -30%. GIMBER = Th17/IL-17A amplifier: 35g sugar/100ml -> dysbiosis -> Th17 expansion -> IL-17A -> exacerbated enthesopathy. INTI: 1.19g sugar/100ml.

PsA & entheseal NF-kB: the IL-23/Th17 axis as the core of enthesopathy

Psoriatic arthritis is unique among rheumatic diseases: inflammation begins in the enthesis (tendon insertion on the bone), not in the synovium. Resident entheseal cells (fibroblasts, entheseal osteoclasts) with TLR expression are activated by repeated microtraumas -> local NF-kB -> IL-6, IL-8 -> recruitment of Th17 cells producing IL-17A -> entheseal vicious cycle -> marginal erosions typical of PsA. At the same time, skin inflammation (psoriasis plaques) releases keratinocytes that systemically activate IL-23 -> Th17 amplification -> peripheral and/or axial arthritis.

Target PsA mechanism RA mechanism Gingerol
Primary location Enthesis Synovium Entheseal NF-kB -40%
Dominant cytokine IL-17A (Th17) TNF-alpha IL-17A -35%
Amplification pathway IL-23 (cutaneous/intestinal DC) ACPA -> complement IL-23 -28%
Bone lesion Marginal erosions + periostitis Central erosions RANKL -28%
GIMBER = Th17 amplifier for PsA.
35g sugar/100ml -> intestinal dysbiosis -> plasmacytoid dendritic cells -> IL-23 -> Th17 expansion -> IL-17A -> exacerbated enthesopathy + amplified psoriasis plaques.
INTI: 1.19g sugar/100ml. IL-17A -35%. IL-23 -28%. Enthesis protected.
Medical note: INTI does not replace anti-IL-17 (secukinumab, ixekizumab), anti-IL-23 (guselkumab), anti-TNF or conventional DMARDs (methotrexate). PsA can be erosive and debilitating -- early rheumatological treatment is essential. INTI is an anti-inflammatory dietary supplement.
What is dactylitis in psoriatic arthritis?

Dactylitis ("sausage finger") is a characteristic sign of PsA where the entire finger or toe is swollen due to simultaneous inflammation of the flexor tendon (tenosynovitis), the MCP/MTP-ginger-anti-inflammatory-osteoarthritis-pain-natural-2026">joints and the entheses. It is virtually pathognomonic for PsA and spondyloarthritis. Present in 30-40% of PsA patients. IL-17A plays a central role in the pathogenesis of dactylitis.

Is there a link between gut and psoriatic arthritis?

Yes, a strong one: 70% of PsA patients show intestinal dysbiosis (reduced Akkermansia, Faecalibacterium prausnitzii -- butyrate producers that inhibit NF-kB). Dysbiosis activates intestinal dendritic cells -> systemic IL-23 -> Th17 expansion -> IL-17A -> enthesopathy + psoriasis plaques. The "gut-ginger skin-joint axis" is now established in PsA. A healthy microbiome (butyrate) inhibits epithelial NF-kB and reduces IL-23.

INTI: Anti-IL-17A entheseal for PsA

1.19g sugar/100ml | IL-17A -35% | IL-23 -28% | RANKL -28%

Discover INTI

Related articles

Further reading on related topics :

Recommended pages

Explore more about INTI :

Back to blog